In this webinar, Drs. Anna Georgiopoulos and Traci Kazmerski shared some of the research and care highlights from the 2023 North American Cystic Fibrosis Conference (NACFC). They also answered audience questions. The program was moderated by Nicole Kohr, an adult with CF. Topics included mental health, genetic therapies, sexual and reproductive health, and lung transplant.

Originally recorded December 5, 2023.

0:00:00 | NACFC Highlights Webinar
0:05:32 | What is the pathway of CF disease?
0:05:58 | What is the latest update on modulator therapy?
0:07:07 | What was the result of the trial testing whether those with an N1303K mutation can benefit from Trikafta®?
0:09:26 | What did a study show about the effect of discontinuing either dornase alfa or hypertonic saline for those taking modulators?
0:12:30 | What are genetic therapies and how do they work?
0:14:50 | What is the latest news on clinical trials for genetic therapies for CF?
0:17:41 | What is the latest research on CF infections?
0:29:20 | What is the latest mental health research?
0:38:51 | What is the latest research on cannabis use in CF?
0:43:05 | Does Trikafta have an effect on nighttime use of oxygen?
0:43:59 | What are the new guidelines in post-transplant care?
0:46:36 | What are the social risk factors for disparities in CF outcomes?
0:49:00 | Will people with CF who start modulators when they are young recover their fertility?
0:51:20 | What research is happening for women’s sexual and reproductive health?
0:52:27 | What do we know about memory and brain fog when on a modulator such as Trikafta?
0:57:36 | Is there any research on discontinuing chest physical therapy or vest therapy once you go on modulators?
0:59:23 | Have there been studies looking at anti-anxiety medications, such as Lexapro, for possible interactions with modulators?
1:01:38 | Is the CRISPR technology that is used to treat sickle cell disease being considered to edit CF genes?
1:02:52 | Are there any intentions on developing a modulator for infants or newborns?
1:03:58 | Are there any modulators in the works for those who do not have an F508del mutation?
1:05:36 | How would you be able to assess potential mental health challenges in infants and young children if they were to take modulators?
1:07:03 | As people need increased specialists and general medical care, is there any talk of building a larger network of interdisciplinary teams? Do we know if we are going to be adding roles?

свернуть